4D Molecular Therapeutics Inc
FDMT10.500USD
-0.420-3.85%
收盤 11/07, 16:00（美東）報價延遲15分鐘
490.35M總市值
虧損本益比TTM
關於 4D Molecular Therapeutics Inc 公司
4D Molecular Therapeutics, Inc. 是一家臨牀階段的基因藥物公司，專注於充分發揮基因藥物在治療眼科和肺病方面的潛力。該公司擁有一系列基因藥物候選產品，其中五種候選產品正在七種患者羣體中進行臨牀試驗：4D-150 用於治療溼性老年性黃斑變性 (wet AMD) 和糖尿病性黃斑水腫 (DME)，4D-710 用於治療囊性纖維化肺病（調節劑不合格和合格人羣），4D-310 用於治療法布里病心肌病，4D-125 用於治療 X 連鎖視網膜色素變性 (XLRP)，4D-110 用於治療脈絡膜缺失。此外，該公司還有兩種處於臨牀前開發階段的產品候選藥物：用於治療地圖樣萎縮（GA）的4D-175和用於治療α-1抗胰蛋白酶缺乏肺病的4D-725。
4D Molecular Therapeutics Inc簡介
公司代碼FDMT
公司名稱4D Molecular Therapeutics Inc
上市日期Dec 11, 2020
CEODr. David Kirn, M.D.
員工數量227
證券類型Ordinary Share
年結日Dec 11
公司地址5858 Horton Street #455
城市EMERYVILLE
上市交易所NASDAQ Global Select Consolidated
國家United States of America
郵編94608
電話15105052680
網址https://4dmoleculartherapeutics.com/
公司代碼FDMT
上市日期Dec 11, 2020
CEODr. David Kirn, M.D.
4D Molecular Therapeutics Inc公司高管
名稱
名稱/職務
職務
持股
持股變動
Dr. David Kirn, M.D.
Dr. David Kirn, M.D.
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
1.66M
-0.02%
Dr. John F. Milligan, Ph.D.
Dr. John F. Milligan, Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
100.00K
--
Mr. Ashoo Gupta
Mr. Ashoo Gupta
Principal Financial Officer, Principal Accounting Officer
Principal Financial Officer, Principal Accounting Officer
45.66K
--
Dr. Fariborz (Fred) Kamal, Ph.D.
Dr. Fariborz (Fred) Kamal, Ph.D.
President, Chief Operating Officer
President, Chief Operating Officer
5.94K
--
Dr. Scott Bizily, J.D., Ph.D.
Dr. Scott Bizily, J.D., Ph.D.
Chief Legal Officer and Corporate Secretary
Chief Legal Officer and Corporate Secretary
--
--
Dr. Dhaval Desai, Pharm.D.
Dr. Dhaval Desai, Pharm.D.
Chief Development Officer
Chief Development Officer
--
--
Dr. Charles P. Theuer, M.D., Ph.D.
Dr. Charles P. Theuer, M.D., Ph.D.
Independent Director
Independent Director
--
--
Ms. Nancy Miller-Rich
Ms. Nancy Miller-Rich
Independent Director
Independent Director
--
--
Dr. Jacob M. Chacko, M.D.
Dr. Jacob M. Chacko, M.D.
Independent Director
Independent Director
--
--
Mr. Christopher (Chris) Simms
Mr. Christopher (Chris) Simms
Chief Commercial Officer
Chief Commercial Officer
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. David Kirn, M.D.
Dr. David Kirn, M.D.
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
1.66M
-0.02%
Dr. John F. Milligan, Ph.D.
Dr. John F. Milligan, Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
100.00K
--
Mr. Ashoo Gupta
Mr. Ashoo Gupta
Principal Financial Officer, Principal Accounting Officer
Principal Financial Officer, Principal Accounting Officer
45.66K
--
Dr. Fariborz (Fred) Kamal, Ph.D.
Dr. Fariborz (Fred) Kamal, Ph.D.
President, Chief Operating Officer
President, Chief Operating Officer
5.94K
--
Dr. Scott Bizily, J.D., Ph.D.
Dr. Scott Bizily, J.D., Ph.D.
Chief Legal Officer and Corporate Secretary
Chief Legal Officer and Corporate Secretary
--
--
Dr. Dhaval Desai, Pharm.D.
Dr. Dhaval Desai, Pharm.D.
Chief Development Officer
Chief Development Officer
--
--
收入明細
單位: USD更新時間: 10月6日 週一
單位: USD更新時間: 10月6日 週一
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
暫無數據
地區USD
名稱
營收
佔比
United States
15.00K
0.00%
Netherlands
0.00
0.00%
業務
地區
暫無數據
股東統計
更新時間: 11月8日 週六
更新時間: 11月8日 週六
持股股東
股東類型
持股股東
持股股東
佔比
BVF Partners L.P.
9.91%
RA Capital Management, LP
9.77%
Goldman Sachs & Company, Inc.
8.01%
Novo Holdings A/S
6.80%
BlackRock Institutional Trust Company, N.A.
6.67%
其他
58.84%
持股股東
持股股東
佔比
BVF Partners L.P.
9.91%
RA Capital Management, LP
9.77%
Goldman Sachs & Company, Inc.
8.01%
Novo Holdings A/S
6.80%
BlackRock Institutional Trust Company, N.A.
6.67%
其他
58.84%
股東類型
持股股東
佔比
Investment Advisor
19.79%
Investment Advisor/Hedge Fund
19.57%
Hedge Fund
17.68%
Venture Capital
17.25%
Research Firm
14.76%
Individual Investor
3.95%
Pension Fund
0.15%
Sovereign Wealth Fund
0.12%
Bank and Trust
0.11%
其他
6.63%
機構持股
更新時間: 10月1日 週三
更新時間: 10月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
353
39.94M
73.19%
-18.33M
2025Q2
351
46.37M
100.09%
-13.01M
2025Q1
358
46.38M
99.71%
-13.16M
2024Q4
357
49.60M
107.13%
-13.93M
2024Q3
350
60.77M
117.85%
-4.39M
2024Q2
340
60.30M
117.01%
-2.54M
2024Q1
324
59.47M
116.84%
+10.27M
2023Q4
284
45.54M
106.82%
-1.53M
2023Q3
275
45.63M
108.12%
-4.94M
2023Q2
263
44.82M
109.79%
-393.70K
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
BVF Partners L.P.
4.63M
9.91%
+68.00K
+1.49%
Jun 30, 2025
RA Capital Management, LP
4.56M
9.77%
--
--
Jun 30, 2025
Goldman Sachs & Company, Inc.
3.74M
8.01%
-7.99K
-0.21%
Jun 30, 2025
Novo Holdings A/S
2.00M
4.28%
+50.00K
+2.56%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
3.12M
6.67%
-415.30K
-11.76%
Jun 30, 2025
The Vanguard Group, Inc.
2.74M
5.86%
-20.82K
-0.75%
Jun 30, 2025
Janus Henderson Investors
1.75M
3.76%
-137.53K
-7.27%
Jun 30, 2025
Kirn (David)
1.66M
3.55%
-360.00
-0.02%
Apr 24, 2025
Federated MDTA LLC
1.65M
3.54%
+411.45K
+33.10%
Jun 30, 2025
Millennium Management LLC
1.48M
3.18%
-150.26K
-9.20%
Jun 30, 2025
查看更多
持股ETF
更新時間: 11月6日 週四
更新時間: 11月6日 週四
機構名稱
佔比
Federated Hermes MDT Small Cap Core ETF
0.59%
iShares Micro-Cap ETF
0.07%
Harbor Human Capital Factor US Small Cap ETF
0.07%
iShares Health Innovation Active ETF
0.05%
ProShares Ultra Nasdaq Biotechnology
0.04%
Invesco Nasdaq Biotechnology ETF
0.04%
iShares Biotechnology ETF
0.04%
Invesco RAFI US 1500 Small-Mid ETF
0.03%
Avantis US Small Cap Equity ETF
0.03%
iShares Russell 2000 Value ETF
0.02%
查看更多
Federated Hermes MDT Small Cap Core ETF
佔比0.59%
iShares Micro-Cap ETF
佔比0.07%
Harbor Human Capital Factor US Small Cap ETF
佔比0.07%
iShares Health Innovation Active ETF
佔比0.05%
ProShares Ultra Nasdaq Biotechnology
佔比0.04%
Invesco Nasdaq Biotechnology ETF
佔比0.04%
iShares Biotechnology ETF
佔比0.04%
Invesco RAFI US 1500 Small-Mid ETF
佔比0.03%
Avantis US Small Cap Equity ETF
佔比0.03%
iShares Russell 2000 Value ETF
佔比0.02%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
